As King’s College London (KCL) scientists are once more in the headlines – this time with new ‘plug and play’ drug delivery technology that could offer a
GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial.<